Empreses emergents
2010
INBIOMOTION SL (Previously SUPRAGEN SL)Desenvolupament d'estratègies personalitzades de tractament adjuvant per al càncer de mama en fase inicial L'assaig diagnòstic únic es basa en un biomarcador d'un sol gen altament selectiu del gen MAF
Adreça
Carrer de París 175, 08036 Barcelona, Espanya
Dades financeres
Propietat CERCA
Barcelona, Spain
2005
Institut de Recerca Biomèdica (IRB Barcelona)
Contacte del Centre CERCA
CH
Cristina Horcajada
Institut de Recerca Biomèdica (IRB Barcelona)Altres accionistes públics catalans
Logotip
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
Inbiomotion focuses on providing a unique companion diagnostic solution, to address an urgent and unmet medical need in the personalized adjuvant treatment of early-stage breast cancer.
Founded in 2010 by Prof. Roger Gomis, Inbiomotion is a spin-off of IRB Barcelona and ICREA research institutions.
Founded in 2010 by Prof. Roger Gomis, Inbiomotion is a spin-off of IRB Barcelona and ICREA research institutions.
Descripció del producte
Proprietary MAF Test: a unique companion diagnostic assay consisting of a highly adaptable in vitro diagnostic kit with automation potential
We address a massive companion diagnostics market globally, to face the steadily increasing rates of breast cancer in women worldwide
On-track to commercialize in 2022
Inbiomotion has generated two large sets of prospective-retrospective data confirming the clinical utility of the MAF Test
MAF test is technically, analytically, and clinically validated by Targos Molecular Pathology GmbH, a leading clinical research organization
Significant barrier to entry, with over 190 granted patents and patent applications
We address a massive companion diagnostics market globally, to face the steadily increasing rates of breast cancer in women worldwide
On-track to commercialize in 2022
Inbiomotion has generated two large sets of prospective-retrospective data confirming the clinical utility of the MAF Test
MAF test is technically, analytically, and clinically validated by Targos Molecular Pathology GmbH, a leading clinical research organization
Significant barrier to entry, with over 190 granted patents and patent applications